Zai Lab (ZLAB) and Argenx (ARGX) announced that China’s National Medical Products Administration, or NMPA, approved the biologics license application, or BLA, for efgartigimod alfa injection, 1,000mg/vial indicated as an add on to standard therapy for the treatment of adult patients with generalized myasthenia gravis, or gMG, who are anti-acetylcholine receptor, or AChR, antibody positive.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLAB: